We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Johnson & Johnson said it will contest a Philadelphia jury’s decision to award $8 billion to a man who claimed its drug Risperdal (risperidone) caused him to grow breasts. Read More
The FDA’s Office of Prescription Drug Promotion (OPDP) sent a warning letter to Galt Pharmaceuticals for sending an email to doctors about its insomnia pill Doral (quazepam) that left out the fact that the drug is a benzodiazepine, a class-four controlled substance. Read More
NICE determined that if erenumab only works as well as botulinum toxin type A, cost-effectiveness estimates are much higher than what it considers acceptable. Read More
Public Citizen has petitioned the FDA to immediately withdraw the approval of AMAG Pharmaceutical’s preterm birth injection Makena (hydroxyprogesterone caproate) because of the failure of a post-market clinical trial. Read More
The Institute for Clinical and Economic Review (ICER) flagged Humira, Rituxan and Lyrica as the top three most costly U.S. drugs in terms of price-hikes in 2017-2018 that were not supported by new clinical evidence. Read More
California’s Governor Gavin Newsom has signed into law the nation’s first legislation barring drugmakers from paying other companies to delay competing generics. Read More